Cabaletta Bio, Inc. CABA
Set alert
1.51 USD -0.07 -4.73%
At close · Oct 30
1.45 -0.06 -3.97%
After hours · Oct 30, 7:44 PM ET
1.43 Day range 1.59
1.35 52-week range 4.15
- YTD
- -31.05%
- 1 year
- -38.87%
- Open
- 1.54
- Prev close
- 1.59
- Mkt cap
- 256.01M
- Vol
- 3.76M
- Avg vol
- 5.20M
- EPS
- -1.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.43
- High
- 1.59
- Forward P/E
- -0.98
- Beta
- 2.42
- Short ratio
- 4.26
- Inst. own
- 100.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.53
- 200-d avg
- 8.16
- 1y target
- 22.22
5Y chart
Events in this range
- Mar 21, 2024Earnings: —; estimate -0.39; surprise —%
- May 15, 2024Earnings: —; estimate -0.48; surprise —%
- May 15, 2024Earnings: -0.51; estimate -0.48; surprise -6.25%
- Aug 8, 2024Earnings: -0.56; estimate -0.55; surprise -1.82%
- Aug 8, 2024Earnings: —; estimate -0.55; surprise —%
- Oct 10, 2024Rating: UBS · — → Buy
- Nov 14, 2024Earnings: -0.62; estimate -0.59; surprise -5.08%
- Nov 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 15, 2024Rating: Wells Fargo · Overweight → Overweight
- Nov 18, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 19, 2024Downgrade: Wells Fargo · Overweight → Equal-Weight
- Dec 20, 2024Downgrade: Evercore ISI Group · Outperform → In-Line
Signals (78)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 7, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 23, 2026 | 7 months ago |
| SMA: Bullish | Jan 19, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 19, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| SMA: Bearish | Jun 9, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| SMA: Bearish | Feb 17, 2025 | 1 year ago |
| SMA: Bullish | Feb 3, 2025 | 1 year ago |
| SMA: Bearish | Jan 20, 2025 | 1 year ago |
| SMA: Bullish | Jan 13, 2025 | 1 year ago |
| RSI: Oversold | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Nov 4, 2024 | 1 year ago |
| SMA: Bearish | Oct 21, 2024 | 2 years ago |
| SMA: Bullish | Oct 14, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 23, 2024 | 2 years ago |
| RSI: Oversold | Aug 5, 2024 | 2 years ago |
| RSI: Oversold | Jun 24, 2024 | 2 years ago |
| SMA: Bearish | Mar 18, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 4, 2024 | 2 years ago |
| SMA: Bullish | Jan 22, 2024 | 2 years ago |
| SMA: Bearish | Jan 15, 2024 | 2 years ago |
| RSI: Overbought | Dec 18, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 6, 2023 | 2 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| SMA: Bearish | Oct 16, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 16, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 11, 2023 | 3 years ago |
| SMA: Bullish | Aug 21, 2023 | 3 years ago |
| SMA: Bearish | Aug 14, 2023 | 3 years ago |
| SMA: Bullish | Aug 7, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 24, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 17, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 10, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 5, 2023 | 3 years ago |
| SMA: Bullish | May 29, 2023 | 3 years ago |
| SMA: Bearish | May 22, 2023 | 3 years ago |
| MACD: Sell Signal | May 22, 2023 | 3 years ago |
| MACD: Buy Signal | May 1, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 6, 2023 | 3 years ago |
| SMA: Bearish | Feb 13, 2023 | 3 years ago |
| RSI: Overbought | Nov 28, 2022 | 3 years ago |
| SMA: Bullish | Oct 17, 2022 | 4 years ago |
| SMA: Bullish | Oct 17, 2022 | 4 years ago |
| RSI: Oversold | Sep 12, 2022 | 4 years ago |
| SMA: Bearish | Aug 29, 2022 | 4 years ago |
| SMA: Bearish | Aug 29, 2022 | 4 years ago |
| SMA: Bullish | Aug 22, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
Key statistics
- Market cap
- 115.35M
- Enterprise value
- -11.18M
- Trailing P/E
- 0.00
- Forward P/E
- -0.98
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.48
- EPS (TTM)
- -2.16
- Beta
- 2.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -45.62M
- Total cash
- 203.22M
- Total debt
- 7.40M
- Return on equity
- -48.16%
- Shares outstanding
- 48.88M
- Short % of float
- 7.84%
- 50-day average
- 3.53
- 200-day average
- 8.16
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 22.22 +1371.7% upside
Now 1.51
- Target (low)
- 6.00
- Target (mean)
- 22.22
- Target (high)
- 35.00
Ratings (0m) 12 10 buy · 2 hold · 0 sell
- Strong buy2
- Buy8
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.64072.
Financials — quick view
CABA Revenue — quarterly 0
CABA Net income — quarterly -51.02M
CABA EPS — quarterly -0.34
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.59 | -0.62 | -0.03 | -5.08% |
| Aug 8, 2024 | Jun 1, 2024 | -0.55 | -0.56 | -0.01 | -1.82% |
| Aug 8, 2024 | Jun 1, 2024 | -0.55 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.48 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.48 | -0.51 | -0.03 | -6.25% |
| Mar 21, 2024 | Dec 1, 2023 | -0.39 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | Evercore ISI Group | down | Outperform | In-Line |
| Dec 19, 2024 | Wells Fargo | down | Overweight | Equal-Weight |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | Wells Fargo | main | Overweight | Overweight |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 10, 2024 | UBS | init | — | Buy |
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cabalettabio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on CABA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BINDER GWENDOLYN | Officer | Conversion of Exercise of derivative security | Jan 18, 2024 | 20,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Jennison Associates LLC | 11.52% | 5,632,681 | 13.29M | Sep 29, 2024 |
| Blackrock Inc. | 9.81% | 4,793,484 | 11.31M | Sep 29, 2024 |
| Fred Alger Management, LLC | 8.43% | 4,119,394 | 9.72M | Sep 29, 2024 |
| T. Rowe Price Investment Management, Inc. | 7.52% | 3,673,724 | 8.67M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 6.21% | 3,036,645 | 7.17M | Sep 29, 2024 |
| Bain Capital Life Sciences Investors, LLC | 5.65% | 2,760,888 | 6.52M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Small-Cap Value Fund | 4.18% | 2,041,663 | 4.82M | Sep 29, 2024 |
| Alger Small Cap Focus Fund | 3.11% | 1,519,064 | 3.58M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.87% | 1,401,191 | 3.31M | Sep 29, 2024 |
| PGIM Jennison Health Sciences Fd | 2.82% | 1,378,804 | 3.25M | Oct 30, 2024 |
| PGIM Jennison Small Company Fd | 2.63% | 1,286,536 | 3.04M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 2.29% | 1,116,866 | 2.64M | Oct 30, 2024 |